These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1353595)

  • 21. [Bone density in differentiated cancer of the thyroid gland treated by hormone-suppressive therapy. Study based on 51 cases].
    Eulry F; Bauduceau B; Lechevalier D; Magnin J; Crozes P; Flageat J; Gautier D
    Rev Rhum Mal Osteoartic; 1992 Apr; 59(4):247-52. PubMed ID: 1496271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy.
    Mazokopakis EE; Starakis IK; Papadomanolaki MG; Batistakis AG; Papadakis JA
    Curr Med Res Opin; 2006 Jul; 22(7):1369-73. PubMed ID: 16834835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Author of "Thyroid administration" article responds to commentary.
    Loberg EL
    Angle Orthod; 1994; 64(6):404. PubMed ID: 7864460
    [No Abstract]   [Full Text] [Related]  

  • 24. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
    Marcocci C; Golia F; Vignali E; Pinchera A
    J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study.
    Appetecchia M
    Horm Res; 2005; 64(6):293-8. PubMed ID: 16269872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes of bone mineral density, quantitative ultrasound parameters and markers of bone turnover during treatment of hyperthyroidism.
    van de Ven AC; Erdtsieck RJ
    Neth J Med; 2008 Nov; 66(10):428-32. PubMed ID: 19011269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.
    Marcocci C; Golia F; Bruno-Bossio G; Vignali E; Pinchera A
    J Clin Endocrinol Metab; 1994 Apr; 78(4):818-23. PubMed ID: 8157704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The risk factors and bone mineral density in women on long-term levothyroxine treatment].
    López Alvarez MB; Hawkins F; Rigopoulou D; Martínez G; Jodar E; Estenoz J; Ortuño B; Arnaiz F
    Med Clin (Barc); 1999 Jan; 112(3):85-9. PubMed ID: 10074614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate.
    Rosen HN; Moses AC; Garber J; Ross DS; Lee SL; Ferguson L; Chen V; Lee K; Greenspan SL
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2324-30. PubMed ID: 9661603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study.
    Bauer M; Fairbanks L; Berghöfer A; Hierholzer J; Bschor T; Baethge C; Rasgon N; Sasse J; Whybrow PC
    J Affect Disord; 2004 Dec; 83(2-3):183-90. PubMed ID: 15555712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thyroid hormone levels affected by time of blood sampling in thyroxine-treated patients.
    Ain KB; Pucino F; Shiver TM; Banks SM
    Thyroid; 1993; 3(2):81-5. PubMed ID: 8369656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bone tissue mineral density in patients with thyroid gland cancer on levothyroxine natrium therapy].
    Khmara IM; Tolkachev IuV
    Klin Med (Mosk); 2005; 83(10):61-5. PubMed ID: 16320850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased bone density and thyroxine.
    Heath H
    JAMA; 1988 Oct; 260(15):2219-20. PubMed ID: 3172402
    [No Abstract]   [Full Text] [Related]  

  • 34. [Prolonged suppressive L-thyroxine therapy. Longitudinal study of the effect of LT4 on bone mineral density and bone metabolism markers in 71 patients].
    Rachedi F; Rohmer V; Six P; Duquenne M; Wion Barbot N; Minebois A; Bigorgne JC; Audran M
    Presse Med; 1999 Feb; 28(7):323-9. PubMed ID: 10083873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone mineral density and L-thyroxine treatment in rapidly cycling bipolar disorder.
    Gyulai L; Jaggi J; Bauer MS; Younkin S; Rubin L; Attie M; Whybrow PC
    Biol Psychiatry; 1997 Feb; 41(4):503-6. PubMed ID: 9034547
    [No Abstract]   [Full Text] [Related]  

  • 36. Bone mineral density and metabolism in levothyroxine-treated adolescent girls with euthyroid diffuse goiter.
    Matusik P; Małecka-Tendera E; Franek E; Januszek-Trzciakowska A
    Endokrynol Pol; 2010; 61(1):14-9. PubMed ID: 20205099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
    Ongphiphadhanakul B; Puavilai G; Rajatanavin R
    J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
    Florkowski CM; Brownlie BE; Elliot JR; Ayling EM; Turner JG
    N Z Med J; 1993 Oct; 106(966):443-4. PubMed ID: 8233173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
    Diamond T; Nery L; Hales I
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1184-8. PubMed ID: 2026740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women.
    Fujiyama K; Kiriyama T; Ito M; Kimura H; Ashizawa K; Tsuruta M; Nagayama Y; Villadolid MC; Yokoyama N; Nagataki S
    Thyroid; 1995 Feb; 5(1):13-7. PubMed ID: 7787427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.